Şunu aradınız:: open label extension (İngilizce - Maltaca)

open label extension phase
fażi ta’ estensjoni open label

open-label extension period
perjodu ta’ estensjoni open label

key: ole = open label extension.
key: ole = estensjoni b’tikketta miftuħa.

long-term, open label extension studies
studji ta’ estenzjoni fit-tul open label

study 4: open-label extension study
studju 4: studju ta’ estensjoni open-label

open-label uncontrolled extension study in adults
studju ta' estensjoni mhux ikkontrollat open-label fl-adulti

open-label, uncontrolled, extension studies in paediatric patients
studji ta' estensjoni, mhux ikkontrollati, b'tikketta mikxufa f'pazjenti pedjatriċi

subsequent episodes of hae were treated in an open label extension.
episodji suċċessivi ta’ hae ġew trattati f’estensjoni open label.

open-label extension study in the treatment of postmenopausal osteoporosis
studju ta’ estensjoni open-label fil-kura ta’ osteoporożi ta’ wara l-menopawża

improved physical function continued during the open label extension up to week 136.
it-titjib fil-funzjoni fiżika tkompla matul l-estensjoni open-label sa Ġimgħa 136.

continued durable responses have been seen for up to 48 months in open-label extension
baqgħu jidhru risponsi fit- tul sa 48 xahar fl - istudji open- label ta ’ kura li kompliet meta l- pazjenti ħadu enbrel mingħajr interruzzjoni; m’ hemmx esperjenza fuq tul ta ’ żmien itwal.

acr responses were maintained in the open-label extension study for up to 136 weeks.
fl-istudju ta’ estensjoni open-label, ir-risponsi għall-acr ġew mantenuti sa 136 ġimgħa.

study pr-018 was a 12-month open-label extension of study pr-011.
studju pr-018 kien estensjoni bit-tikketta mikxufa ta’ 12-il xahar tal-istudju pr-011.

patients enrolled into the pivotal study were eligible to enter a long term open label extension study.
pazjenti mdaħħla fl-istudju pivitali kienu eliġibbli li jidħlu fi studju estiż b’tikketta miftuħa fuq tul ta’ żmien twil.

one patient was diagnosed with multiple sclerosis while in period c (open-label extension).
pazjent wieħed kien iddijanjostikat bi sklerosi multipla meta kien f’perjodu Ċ (estensjoni open-label).

after the first year of the study, 53 patients continued into an open-label extension to week 102.
wara l-ewwel sena tal-istudju, 53 pazjent komplew fuq estensjoni open-label sa ġimgħa 102.

week 98 data for impact includes combined placebo crossover and infliximab patients who entered the open-label extension
dejta ta’ Ġimgħa 98 għal impact jinkludi plaċebo kombinat crossover u pazjenti fuq infliximab li daħlu għall-estensjoni open-label

a total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open- label extension study.
fi studju ta’ estensjoni open-label, total ta’ 347 pazjent li kellhom rispons stabbli għall-kura pparteċipaw f’evalwazzjoni ta’ x’jiġri meta titwaqqaf u terġa’ tinbeda l-kura.

an open-label extension study (chest-2) included 237 patients who had completed chest-1.
studju open-label ta’ estensjoni (chest-2) kien jinkludi 237 pazjent li kienu temmew chest-1.

in the ert- naïve trial and open label extension, renal function remained stable for 3 years of treatment with galafold.
fil-prova mingħajr esperjenza tal-ert u l-estensjoni open-label, il-funzjoni tal-kliewi baqgħet stabbli għal 3 snin ta' kura b'galafold.